Skip to main content

Table 2 Clinical Characteristics and Therapeutic Efficacy in Patients with Newly Diagnosed Adult NKTCL (n = 33)

From: PEG-L-CHOP treatment is safe and effective in adult extranodal NK/T-cell lymphoma with a low rate of clinical hypersensitivity

Characteristic

Patients (%)

CR (%)

NO CR (%)

p value

Age

 <60 years

30 (90.9)

23 (76.7)

7 (23.3)

1.000

 ≥ 60 years

3 (9.1)

2 (66.7)

1 (33.3)

 

Gender

 Male

19 (57.6)

16 (84.2)

3 (15.8)

0.238

 Female

14 (42.2)

9 (64.3)

5 (35.7)

 

Primary site

 UNKTCL

30 (90.9)

23 (76.7)

7 (23.3)

1.000

 EUNKTCL

3 (9.1)

2 (66.7)

1 (33.3)

 

An Arbor Stage

 I~II

21 (63.6)

19 (90.5)

2 (9.5)

0.015*

 III~IV

12 (36.4)

6 (50.0)

6 (50.0)

 

B symptom

 Yes

12 (36.4)

9 (75.0)

3 (25.0)

1.000

 No

21 (63.6)

16 (76.2)

5 (23.8)

 

ECOG

 0–1

27 (81.8)

21 (77.8)

6 (22.2)

0.616

 ≥ 2

6 (18.2)

4 (66.7)

2 (33.3)

 

LDH

 Increased

7 (21.2)

2 (28.6)

5 (71.4)

0.004*

 Normal

26 (78.8)

23 (88.5)

3 (11.5)

 

IPI score

 0~ 1

22 (66.7)

21 (95.5)

1 (4.5)

< 0.001*

 ≥ 2

11 (33.3)

4 (36.4)

7 (63.6)

 

β2-microglobulin

 Increased

8 (24.2)

5 (62.5)

3 (37.5)

0.366

 Normal

25 (75.8)

20 (80.0)

5 (20.0)

 

BM involvement

 Yes

4 (12.1)

3 (75.0)

1 (25.0)

1.000

 No

29 (87.9)

22 (75.9)

7 (24.1)

 

Lymph node involvement

 Yes

12 (36.4)

9 (75.0)

3 (25.0)

1.000

 No

21 (63.6)

16 (76.2)

5 (23.8)

 

Extranodal involvement site

 0–1

26 (78.8)

22 (84.6)

4 (15.4)

0.042

 ≥ 2

7 (21.2)

3 (42.9)

4 (57.1)

 

Allergy history

 Yes

1 (3.0)

0 (0.0)

1 (100.0)

0.242

 No

32 (97.0)

25 (78.1)

7 (21.9)

 
  1. Abbreviations: CR complete remission, No CR included PR partial remission, SD stable disease and PD progressive disease
  2. *Fisher’s exact test, sample sizes in some cells are 5 or less